Clinical Trial Update: Phase 2 Study of NV-5138 in Adults With Treatment Resistant Depression [Phase 2]

View source ↗

Summary

Navitor Pharmaceuticals announced completion of the Phase 2 study of NV-5138 in adults with treatment-resistant depression, and the results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Treatment-resistant Depression

Drugs mentioned

• NV-5138

Snippet

Sponsor: Navitor Pharmaceuticals, Inc. | Conditions: Treatment Resistant Depression | Phase 2 | Status: COMPLETED | Results posted: 2026-04-17